JP2023542065A5 - - Google Patents

Info

Publication number
JP2023542065A5
JP2023542065A5 JP2022580314A JP2022580314A JP2023542065A5 JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5 JP 2022580314 A JP2022580314 A JP 2022580314A JP 2022580314 A JP2022580314 A JP 2022580314A JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
cancer
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580314A
Other languages
English (en)
Japanese (ja)
Other versions
JP7794766B2 (ja
JP2023542065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055547 external-priority patent/WO2021260578A1/en
Publication of JP2023542065A publication Critical patent/JP2023542065A/ja
Publication of JP2023542065A5 publication Critical patent/JP2023542065A5/ja
Priority to JP2025264238A priority Critical patent/JP2026048890A/ja
Application granted granted Critical
Publication of JP7794766B2 publication Critical patent/JP7794766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580314A 2020-06-24 2021-06-23 抗体-薬物複合物及びcdk9阻害剤の組み合わせ Active JP7794766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025264238A JP2026048890A (ja) 2020-06-24 2025-12-18 抗体-薬物複合物及びcdk9阻害剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043528P 2020-06-24 2020-06-24
US63/043,528 2020-06-24
PCT/IB2021/055547 WO2021260578A1 (en) 2020-06-24 2021-06-23 Combination of antibody-drug conjugate and cdk9 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025264238A Division JP2026048890A (ja) 2020-06-24 2025-12-18 抗体-薬物複合物及びcdk9阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2023542065A JP2023542065A (ja) 2023-10-05
JP2023542065A5 true JP2023542065A5 (cg-RX-API-DMAC7.html) 2024-06-24
JP7794766B2 JP7794766B2 (ja) 2026-01-06

Family

ID=76971937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580314A Active JP7794766B2 (ja) 2020-06-24 2021-06-23 抗体-薬物複合物及びcdk9阻害剤の組み合わせ
JP2025264238A Pending JP2026048890A (ja) 2020-06-24 2025-12-18 抗体-薬物複合物及びcdk9阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025264238A Pending JP2026048890A (ja) 2020-06-24 2025-12-18 抗体-薬物複合物及びcdk9阻害剤の組み合わせ

Country Status (6)

Country Link
US (1) US20230233540A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171654A1 (cg-RX-API-DMAC7.html)
JP (2) JP7794766B2 (cg-RX-API-DMAC7.html)
CN (1) CN116615248A (cg-RX-API-DMAC7.html)
TW (1) TW202216207A (cg-RX-API-DMAC7.html)
WO (1) WO2021260578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3249707A1 (en) * 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
CN116712561A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
WO2025054996A1 (en) * 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025162211A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胃癌的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TR201909286T4 (tr) 2015-06-29 2019-07-22 Astrazeneca Ab CDK9 inhibitörleri olarak polisiklik amid türevleri.
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Similar Documents

Publication Publication Date Title
JP2023539715A5 (cg-RX-API-DMAC7.html)
JP2023542066A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
JP2023525120A5 (cg-RX-API-DMAC7.html)
JP2025160318A5 (cg-RX-API-DMAC7.html)
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
JP2024530495A5 (cg-RX-API-DMAC7.html)
JP2025041725A5 (cg-RX-API-DMAC7.html)
JP2023515235A5 (cg-RX-API-DMAC7.html)
JPWO2020130125A5 (cg-RX-API-DMAC7.html)
JP2022515198A5 (cg-RX-API-DMAC7.html)
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2020007311A5 (cg-RX-API-DMAC7.html)
JP2023070678A5 (cg-RX-API-DMAC7.html)
JP2017095457A5 (cg-RX-API-DMAC7.html)
FI4212552T3 (fi) Anti-her2-vasta-aine-lääkeainekonjugaatti
JP2017186337A5 (cg-RX-API-DMAC7.html)
RU2016130986A (ru) Ингибитор киназы и его применение
JP2017506234A5 (cg-RX-API-DMAC7.html)
ME02928B (me) Dll3 modulatori i metode upotrebe
JP2022540890A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
JP2026504636A5 (cg-RX-API-DMAC7.html)
JP2024523422A5 (cg-RX-API-DMAC7.html)
JP2024532845A5 (cg-RX-API-DMAC7.html)